Explore News By Topic

03/13/2017

PCF-Funded Research Reveals Gene Mutation as Driver of Prostate Cancer Subtype

A newly discovered genetic mutation that is found in a subtype of prostate cancer is integral to the disease’s development and growth, according to research from Weill Cornell Medicine scientists. Their findings could pave the way for new targeted treatment approaches. A mutation of the gene Speckle Type BTB/POZ Protein, or.

03/02/2017

Study by PCF-Young Investigator identifies how cancer cells may develop resistance to FGFR inhibitors

Columbus, Ohio - A new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor.

02/13/2017

PCF-Funded Research at the Cleveland Clinic Identifies how to Reverse Prostate Cancer Drug Resistance

A Cleveland Clinic research team has uncovered a biological pathway that renders a common prostate cancer drug useless and, for the first time, restored the drug’s cancer-killing power in human prostate cancer tumor cells grown in mice. Results from the study were published online today in the medical journal, eLife..

01/25/2017

PCF Statement On Nomination Of Dr. David Shulkin As VA Secretary

SANTA MONICA, CA—January 25, 2016—President and CEO of the of the Prostate Cancer Foundation, Dr. Jonathan W. Simons, MD, today released the following statement regarding President Donald J. Trump’s nominee to be secretary of the U.S. Department of Veterans Affairs (VA). Dr. Shulkin is currently serving as the undersecretary for.

01/05/2017

Roswell Park Research Helps Explain Why Androgen-Deprivation Therapy Doesn’t Work for Many Prostate Cancers

BUFFALO, N.Y. (Roswell Park Cancer Institute) — Metastatic prostate cancer, or prostate cancer that has spread to other organs, is incurable. In new research published in the journal Science, Roswell Park Cancer Institute scientists have identified two gatekeeper genes that allow prostate cancer to progress and resist treatment. Their work.

12/20/2016

Breast Cancer Research Foundation and Prostate Cancer Foundation Announce Their Commitment to Support the Blood Profiling Atlas in Cancer

In alignment with VP Biden’s Cancer Moonshot initiative, the Blood PAC formed in October 2016 to support progress towards patient benefit through research.

12/08/2016

Prostate Cancer Foundation Statement on the Historic 21st Century Cures Act

The Prostate Cancer Foundation (PCF) applauds Congress and the White House for the strong, bipartisan show of support for the 21st Century Cures Act (H.R. 34). Following the Senate’s passage  by a vote of 94 to 5, Congressional leaders signed the bill at this morning’s Enrollment Ceremony. The House had previously passed the game-changing medical innovation.

12/01/2016

Holiday Cards Commemorating Musician Dan Fogelberg Now Available Sales Will Benefit The Prostate Cancer Foundation

PR Newswire, SANTA MONICA, CA December 1, 2016 The Prostate Cancer Foundation (PCF) announces that holiday cards designed by Jean Fogelberg in memory of her husband, musician Dan Fogelberg, are now available for purchase. Fogelberg passed away from prostate cancer in 2007 at the age of 56. A portion of.

11/29/2016

VA Partners with Prostate Cancer Foundation to Expand Clinical Research

WASHINGTON – As a national leader in oncology advancement and as the largest integrated healthcare system in the nation, the Department of Veterans Affairs (VA) today announced an important and substantial partnership with the Prostate Cancer Foundation (PCF) to prevent, screen and promote research to speed the development of treatments.